van Dijk F S, Cobben J M, Kariminejad A, Maugeri A, Nikkels P G J, van Rijn R R, Pals G
Department of Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands.
Mol Syndromol. 2011 Dec;2(1):1-20. doi: 10.1159/000332228. Epub 2011 Oct 12.
Osteogenesis imperfecta (OI) is characterized by susceptibility to bone fractures, with a severity ranging from subtle increase in fracture frequency to prenatal fractures. The first scientific description of OI dates from 1788. Since then, important milestones in OI research and treatment have, among others, been the classification of OI into 4 types (the 'Sillence classification'), the discovery of defects in collagen type I biosynthesis as a cause of most cases of OI and the use of bisphosphonate therapy. Furthermore, in the past 5 years, it has become clear that OI comprises a group of heterogeneous disorders, with an estimated 90% of cases due to a causative variant in the COL1A1 or COL1A2 genes and with the remaining 10% due to causative recessive variants in the 8 genes known so far, or in other currently unknown genes. This review aims to highlight the current knowledge around the history, epidemiology, pathogenesis, clinical/radiological features, management, and future prospects of OI. The text will be illustrated with clinical descriptions, including radiographs and, where possible, photographs of patients with OI.
成骨不全症(OI)的特征是易发生骨折,严重程度从骨折频率的轻微增加到产前骨折不等。对OI的首次科学描述可追溯到1788年。从那时起,OI研究和治疗的重要里程碑包括将OI分为4种类型(“西伦斯分类法”)、发现I型胶原蛋白生物合成缺陷是大多数OI病例的病因以及双膦酸盐疗法的应用。此外,在过去5年中,已经明确OI是一组异质性疾病,估计90%的病例是由COL1A1或COL1A2基因的致病变异引起的,其余10%是由目前已知的8个基因或其他目前未知基因中的致病隐性变异引起的。本综述旨在强调关于OI的历史、流行病学、发病机制、临床/放射学特征、管理及未来前景的当前知识。文中将配有临床描述,包括X光片,并在可能的情况下展示OI患者的照片。